Start here if you're new
what it is
It sells robotic systems that guide catheter tips through blood vessels with magnets instead of a doctor’s hand.
how it gets paid
Last year Stereotaxis made $32M in revenue. Genesis RMN systems was the main engine at $12M, or 38% of sales.
why it's growing
Revenue grew 20.3% last year. The 218% revenue jump matters because it shows a tiny base can move fast.
what just happened
Revenue hit $24M while EPS stayed at -$0.19.
At a glance
B balance sheet — gets the job done, barely
65/100 earnings predictability — reasonably predictable
-$0.30 fy2024 eps est
$2B fy2026 rev est
68.3% operating margin
xvary composite: 49/100 — below average
What they do
It sells robotic systems that guide catheter tips through blood vessels with magnets instead of a doctor’s hand.
Manual catheters move from the handle. Stereotaxis moves the tip with magnetic fields, so your doctor is steering the wire without touching it. That matters because the company says direct tip control can improve precision, stability, reach, and safety, and it did that with 139 employees and about 1.5% market share.
How they make money
$32M
annual revenue · their business grew +20.3% last year
Genesis RMN systems
$12M
Odyssey Solution
$8M
Disposable catheters
$7M
Service and accessories
$5M
The products that matter
robotic magnetic navigation platform
Genesis RMN System
$13.0M system revenue · +36%
this is the capital-equipment sale that expands the installed base. system revenue reached $13.0M in 2025, and management pointed to a 36% jump in Q4 system-driven revenue as the demand signal that mattered.
installed base driver
disposable catheter platform
MAGiC Catheter
60% of sales sit in recurring revenue
the catheter matters because it feeds the steadier part of the model. disposables, service, and accessories produced $19.4M in 2025, or 60% of total revenue. That's the part you want carrying more weight next.
recurring revenue bet
service and accessories support
Installed Base Support
150-plus systems
more than 150 systems in the field give Stereotaxis something many early medtech names lack: real usage already exists. The catch is that installed systems only matter if they pull through more revenue, not if they just sit there looking strategic.
proof of adoption
Key numbers
$32M
annual revenue
This is the whole business. You are looking at a company smaller than many single products.
53.7%
gross margin
More than half of sales stayed after direct costs, which is better than the operating line but still not enough to cover expenses.
68.3%
operating margin
For every $1 of sales, the company lost about 68 cents before taxes and interest.
$5M
long-term debt
Debt is only 3% of capital, so the balance sheet is not the main problem. The main problem is profitability.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 10 / 100
- long-term debt $5M (3% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for STXS right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue hit $24M while EPS stayed at -$0.19.
Sales jumped 218% from a year ago, and gross margin was 53.7%. The ugly part is that earnings stayed negative, so growth still has not turned into profit.
$24M
revenue
-$0.19
eps
53.7%
gross margin
the number that mattered
The 218% revenue jump matters because it shows a tiny base can move fast, but the company still lost money.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the main risk is simple: STXS stays a real product with a small business attached to it. At roughly 1.5% share and $32.4M in revenue, this company does not have much room for "almost" scaling.
med
share gains do not arrive
Stereotaxis still sits around ~1.5% market share in surgical robotics. That leaves the company relying on hospitals to choose a niche magnetic-navigation workflow over bigger, better-known alternatives.
At $32.4M in annual revenue, there is not enough scale to shrug off stalled adoption.
med
profitability keeps moving out
Analysts still expect a -$0.30 EPS result, and management is only targeting positive cash flow from operations in 2026. A 53.7% gross margin helps, but it does not solve an expense base spread across a very small company.
If losses persist while revenue stays below $40M+, dilution or retrenchment get easier to imagine.
med
the 2025 inventory build does not convert into growth
Management put $5.6M into working capital in 2025 while building manufacturing and commercial capability. That only looks smart if it supports real volume next.
If 2026 does not show revenue follow-through, the investment starts looking like preparation without payoff.
With $32.4M in 2025 revenue, ~1.5% share, and a $40M+ target for 2026, the gap between interesting technology and durable business is still wide enough to matter.
source: institutional data · regulatory filings · risk analysis
Pay attention to
scoreboard
$40M+ revenue target
Management put the number on the table for 2026. If STXS clears it from a $32.4M base, the scale argument gets more serious.
mix shift
recurring revenue staying above 60% of sales
Disposables, service, and accessories already contribute $19.4M. You want that share rising, because recurring revenue is the cleaner part of the model.
checkpoint
positive cash flow from operations
Management says 2026 is the goal after a $5.6M working capital investment in 2025. That is the clearest proof that growth is becoming operational, not just aspirational.
risk
system demand fading after the q4 jump
Q4 system-driven revenue grew 36%. If that was pull-forward rather than trend, the market will notice fast.
Analyst rankings
earnings predictability
65 / 100
in human-speak, analysts think this story is somewhat readable, but not stable enough to trust quarter to quarter without surprises.
beta
1.45
Beta measures how much a stock moves versus the market. At 1.45, STXS has historically moved more than the index. Not a bunker stock.
source: institutional data
Institutional activity
institutional ownership data for STXS is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$3
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive